尼洛替尼对女性慢性髓性白血病患者妊娠结局的影响
该回顾性研究收集2015年3月至2019年1月接受尼洛替尼治疗期间妊娠的11例女性CML患者,共12例次妊娠。意外妊娠占83.3%,妊娠早期尼洛替尼600 mg/d暴露中位4周,已知生育结果8例次中5例正常婴儿、2例自然流产、1例并指畸形。结论认为妊娠早期暴露可生产正常婴儿,但仍有自然流产和先天畸形风险。
要点
- 妊娠早期尼洛替尼600 mg/d暴露中位4周者多数可生产正常婴儿。
- 意外妊娠比例高,需重视CML女性患者妊娠计划与避孕管理。
- 妊娠早期尼洛替尼暴露仍存在自然流产和先天畸形风险。
核心结论
- 妊娠早期尼洛替尼600 mg/d暴露4周的女性CML患者可生产正常婴儿,但仍有自然流产和生产先天畸形儿的可能。
研究设计与样本
- 回顾性收集2015年3月至2019年1月接受尼洛替尼治疗期间妊娠的CML患者临床资料,共11例患者、12例次妊娠。
主要发现
- 妊娠时中位年龄28(25~40)岁,妊娠前尼洛替尼中位治疗34(3~48)个月。
- 12例次妊娠中计划妊娠2例次,意外妊娠10例次(83.3%)。
- 10例次意外妊娠中妊娠早期尼洛替尼600 mg/d暴露9例(90.0%),中位暴露4(4~7)周。
- 已知生育结果8例次中5例次生产正常婴儿、2例次自然流产、1例次生产并指畸形男婴(母亲妊娠早期尼洛替尼600 mg/d暴露7周)。
- 7例婴儿出生时中位身高50(41~54)cm、中位体重3.2(3.0~4.6)kg,中位年龄19(4~41)个月时生长发育均正常。
关键数值与推荐
- 妊娠期间中位停药35(15~36)周,无患者失去完全血液学反应。
- 12例次妊娠时疾病状态:完全分子学反应3例次、MR(4.0) 2例次、MMR 3例次、未达MMR 4例次。
临床怎么用
- 应加强CML女性患者妊娠计划管理,减少意外妊娠和妊娠早期尼洛替尼暴露。
- 妊娠早期尼洛替尼暴露后需充分告知自然流产和先天畸形风险并密切产前监测。
局限性
- 本研究为回顾性研究,样本量小(11例患者、12例次妊娠),已知生育结果仅8例次。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To observe the pregnancy outcome among patients with chronic myeloid leukemia (CML) treated with Nilotinib (NIL) . Methods: Clinical data of pregnancy delivery in CML patients treated with NIL from March 2015 to January 2019 were retrospectively collected. Results: A total of 11 patients were recruited with median pregnancy age 28 (25-40) years. The median duration of NIL treatment before pregnancy was 34 (3-48) months. There were 12 pregnancies, included 2 planned ones and 10 (83.3%) unplanned. In the 10 unplanned patients, 9 (90.0%) received NIL 600 mg/d. The median exposure time were 4 (4-7) weeks. In eight patients with delivery outcomes, 5 cases had well-developed babies, 2 had spontaneous abortion and 1 case with an baby of syndactyly deformity, whose mother was exposed to NIL 600 mg/d for 7 weeks in the early trimester of pregnancy. Seven infants were 4 boys and 3 girls with the median height at birth 50 (41-54) cm and median weight 3.2 (3.0-4.6) kg. They all grew with a normal pattern and well developed. Now the median age is 19 (4-41) months. The disease status during 12 pregnancies included 3 cases in CMR, 2 cases in MR(4.0), 3 cases in MMR, 4 cases not acquiring MMR. The median time of drug discontinuation was 35 (15-36) weeks during pregnancy. No patient lost CHR during this period. Conclusions: Female CML patients exposed to NIL 600 mg/d for 4 weeks in early pregnancy can give birth to normal babies, but there is still a risk of spontaneous abortion and congenital malformations. 目的: 观察尼洛替尼(NIL)治疗期间女性慢性髓性白血病(CML)患者的妊娠结果。 方法: 回顾性收集2015年3月至2019年1月接受NIL治疗期间妊娠的CML患者的治疗情况和生育相关信息。 结果: 11例患者,妊娠时中位年龄28(25~40)岁。妊娠前NIL中位治疗34(3~48)个月。11例患者共妊娠12例次,计划妊娠2例次,意外妊娠10例次(83.3%)。10例次意外妊娠患者,妊娠早期NIL暴露剂量600 mg/d者9例(90.0%),NIL中位暴露4(4~7)周,NIL暴露4周者8例次(80.0%)。已知生育结果8例次,其中5例次生产正常婴儿,2例次自然流产,1例次生产并指畸形男婴,其母亲妊娠早期NIL 600 mg/d暴露7周。11例女性患者共生产7例婴儿,男4例,女3例,出生时中位身高50(41~54)cm,中位体重3.2(3.0~4.6)kg。目前,7例患者所生子女生长发育均正常,中位年龄19(4~41)个月。12例次患者妊娠时疾病状态:完全分子学反应3例次、分子学反应4.0(MR(4.0))2例次、主要分子学反应(MMR)3例次、未达MMR 4例次,妊娠期间中位停药35(15~36)周,无患者失去完全血液学反应。 结论: 妊娠早期NIL 600 mg/d暴露4周的女性CML患者可生产正常婴儿,但仍有自然流产和生产先天畸形儿的可能。.
引用
- Zhao HF, Song YP, Li Z, et al. [Effect of nilotinib on pregnancy outcome in female patients with chronic myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 32023727. doi:10.3760/cma.j.issn.0253-2727.2019.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。